Peripheral venous route for administration of ammonul infusion for treatment of acute hyperammonemia. An experience from a tertiary center in Saudi Arabia

dc.contributor.authorAlHashem, Amal M.
dc.contributor.authorSalih, Rihab M.
dc.contributor.authorAl-Aqeel, Aida Imbrahim
dc.contributor.authorMohamed, Sarar
dc.contributor.departmentBiochemistry and Molecular Genetics
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:38:04Z
dc.date.available2025-01-24T11:38:04Z
dc.date.issued2020
dc.description.abstractObjectives: To determine the local effects of peripheral Ammonul infusion on the skin and the subcutaneous tissues. Methods: This retrospective study was conducted at Prince Sultan Military Medical City, Riyadh, Saudi Arabia. All children <16 years of age admitted between December 2015 and October 2018 with hyperammonemia and received Ammonul infusion for treatment were recruited. Results: Twenty-one patients received the Ammonul infusion. They were admitted 58 times with acute hyperammonemia during the study period, with an average of 2.8 admissions per patient. The mean age of the included patients was 49.5 months. The most frequent underlying diagnoses were propionic acidemia (n=9), urea cycle disorders (n=5), and intrinsic liver disease (n=3). All participants received Ammonul through peripheral lines except 3 who received it through central lines. No extravasation, burns, or other local side effects were observed in this cohort. Conclusion: This data indicate that the use of Ammonul through a peripheral venous route appears to be safe and not associated with infusion-related local adverse effects. © 2020 Saudi Arabian Armed Forces Hospital. All rights reserved.
dc.identifier.doihttps://doi.org/10.15537/smj.2020.1.24760
dc.identifier.eid2-s2.0-85077698469
dc.identifier.pmid31915802
dc.identifier.urihttp://hdl.handle.net/10938/28974
dc.language.isoen
dc.publisherSaudi Arabian Armed Forces Hospital
dc.relation.ispartofSaudi Medical Journal
dc.sourceScopus
dc.subjectAmmonul
dc.subjectHyperammonemia
dc.subjectSodium benzoate
dc.subjectSodium phenylacetate
dc.subjectAcute disease
dc.subjectAdolescent
dc.subjectChild
dc.subjectFemale
dc.subjectHumans
dc.subjectInfusions, intravenous
dc.subjectMale
dc.subjectRetrospective studies
dc.subjectSaudi arabia
dc.subjectTertiary care centers
dc.subjectBenzoic acid plus phenylacetic acid
dc.subjectCarbamoyl phosphate synthase
dc.subjectPropionyl coenzyme a carboxylase
dc.subjectPyruvate dehydrogenase
dc.subjectArticle
dc.subjectCitrullinemia
dc.subjectClinical article
dc.subjectDrug infusion
dc.subjectGene
dc.subjectGene mutation
dc.subjectHemochromatosis
dc.subjectHuman
dc.subjectInfant
dc.subjectLiver disease
dc.subjectNewborn
dc.subjectObservational study
dc.subjectPrevalence
dc.subjectPropionic acidemia
dc.subjectRetrospective study
dc.subjectSubcutaneous tissue
dc.subjectUrea cycle disorder
dc.subjectIntravenous drug administration
dc.subjectProcedures
dc.subjectTertiary care center
dc.titlePeripheral venous route for administration of ammonul infusion for treatment of acute hyperammonemia. An experience from a tertiary center in Saudi Arabia
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2020-3591.pdf
Size:
248.16 KB
Format:
Adobe Portable Document Format